



SUPPLEMENTARY FIGURES AND TABLE



Supplementary Figure S1: Effect of SR141716 treatment on the apoptotic protein expression profiles of U251 glioma cell line. U251 cells were treated with SR141716 20 μ M for 24 h and cell lysates were used to determine different protein levels through a human array kit/proteome profiler. **A.** Panel shows a representative proteomic membrane analysis with indication of the modified proteins. **B.** Densitometric analysis of the membrane spots reported as pixel densities.



Supplementary Figure S2: Effect of SR141716 treatment on Smad-dependent TGF- β signaling pathway in U251 glioma cell line. U251 cells were treated with SR141716 20 μ M for 18 h and cell lysates were subjected to western blot with anti-phospho-SMAD2/3, anti-phospho-SMAD1/5/8 and the corresponding anti-total-SMAD2/3 and anti-total-SMAD1/5/8 antibodies. α -tubulin monoclonal antibody was used as an internal loading control.

Supplementary Table S1. Clinical characteristics of the patients' cohort

Patient	Survival (months)	Recurrence (months)	Clinical Stage	Age	Gender	Treatment post-lesion
GBM2	15	9	Astro III	44	M	Chemotherapy-Radiotherapy
GBM5	17	38	Glioma II	69	F	Chemotherapy
GBM7	16	free	IV	49	M	Chemotherapy-Radiotherapy
GBM15	9	9	IV	73	M	STUPP Protocol
GBM16	9	free	Astro II	31	M	Wait and See
GBM17	8	9	IV	48	F	Chemotherapy
GBM18	7	4	IV	74	M	Chemotherapy
GBM20	6	free	IV	64	M	STUPP Protocol
GBM21	10	4	IV	57	M	STUPP Protocol
GBM22	8	free	IV	72	F	STUPP Protocol
GBM23	6	free	Astroblastoma	27	M	STUPP Protocol
GBM24	5	residual	IV	65	F	STUPP Protocol
GBM25	5	3	IV	77	F	STUPP Protocol
GBM26	2	residual	IV	66	M	STUPP Protocol
GBM27	2	residual	IV	64	F	STUPP Protocol
GBM28	8	9	III	52	M	STUPP Protocol
GBM29	8	5	IV	43	M	Fotemustine
GBM30	4	1	IV	58	F	STUPP Protocol
GBM31	5	residual	Gliosarcoma	66	M	STUPP Protocol
GBM32	7	7	IV	48	M	Fotemustine
GBM33	5	free	IV	48	F	STUPP Protocol
GBM34	6	1	IV	54	M	STUPP Protocol
GBM35	10	free	IV	41	M	STUPP Protocol